Second-line erlotinib in unselected NSCLC: audit of benefit

被引：0
|
作者：
Urquhart, G. [1 ]
Semple, E. [2 ]
Steven, E. [1 ]
Kerr, K. [1 ]
Nicolson, M. [1 ]
机构：
[1] Aberdeen Royal Infirm, Aberdeen, Scotland
[2] Univ Aberdeen, Sch Med, Aberdeen AB9 2ZD, Scotland
来源：
LUNG CANCER | 2011年 / 71卷
关键词：
D O I：
10.1016/S0169-5002(11)70011-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11
引用
收藏
页码：S4 / S4
页数：1
相关论文
共 50 条
  • [21] Second-line and third-line chemotherapy in malignant gliomas:: Is there a benefit?
    Pace, A.
    Fabi, A.
    Mirri, A.
    Vidiri, A.
    Cianciulli, A.
    Merola, R.
    Galiè, E.
    Maschio, M.
    Jandolo, B.
    Carapella, C. M.
    NEURO-ONCOLOGY, 2006, 8 (04) : 346 - 346
  • [22] Erlotinib in non-small cell lung cancer (NSCLC) in Germany - A cost-saving second-line treatment option?
    Gabriel, A.
    Pirk, O.
    Kotowa, W.
    VALUE IN HEALTH, 2006, 9 (06) : A278 - A278
  • [23] Response to: Bintrafusp Alfa in Second-Line Treatment of Patients With NSCLC
    Paz-Ares, Luis
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : E24 - E24
  • [24] Pattern of use of second-line treatment for NSCLC in the Nordic countries
    Mellemgaard, A.
    Ek, L.
    Riska, H.
    Tell, R.
    EJC SUPPLEMENTS, 2009, 7 (02): : 527 - 527
  • [25] Second line chemotherapy in NSCLC: Middlesbrough cancer centre audit
    Iqbal, S.
    Azribi, F.
    LUNG CANCER, 2012, 75 : S10 - S11
  • [26] Front-line erlotinib in unselected patients with advanced NSCLC and poor performance status - the TOPICAL study
    Karachaliou, Niki
    Wei, Jia
    Marques, Ana Daniela
    Rosell, Rafael
    TRANSLATIONAL LUNG CANCER RESEARCH, 2013, 2 (01) : 58 - 61
  • [27] Second-line erlotinib for non-small-cell lung cancer Reply
    Ciuleanu, Tudor
    LANCET ONCOLOGY, 2012, 13 (04): : E142 - E142
  • [28] A randomized phase II study of pemetrexed versus pemetrexed plus erlotinib in second-line treatment for locally advanced or metastatic, nonsquamous NSCLC
    Von Pawel, J.
    Papai-Szekely, Z.
    Vinolas, N.
    Sederholm, C.
    Klima, M.
    Desaiah, D.
    Leschinger, M. I.
    Dittrich, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [29] Maintenance Therapy versus Early Second-Line Therapy in Advanced NSCLC
    Fidias, Panos
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S167 - S169
  • [30] Pemetrexed in second-line treatment in advanced NSCLC: An experience on 131 patients
    Bearz, A.
    Garassino, I.
    Cavina, R.
    Talamini, R.
    Favaretto, A.
    Boccalon, M.
    Simonelli, C.
    Spazzapan, S.
    Fratino, L.
    Tirelli, U.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345